May 24th 2023
Bill 1196 / Assembly Bill 1673 aims to improve access to precision medicine for patients with cancer in New York by requiring all state-regulated health plans to cover biomarker testing when it is supported by medical and scientific evidence.
High Levels of KRAS in ctDNA of Pancreatic Cancer May Mean Lower OS
January 21st 2015During a retrospective study of 182 patients with nonresectable pancreatic cancer, a negative association was found between baseline circulating tumor (ct)DNA KRAS counts in plasma and overall survival (OS), which indicates that patients with lower KRAS burden in ctDNA survive longer.
Read More
Novartis Buys Into Gene Editing With CRISPR/Cas9
January 12th 2015The start of 2015 brought news from Novartis that it had signed an agreement with Intellia Therapeutics and Caribou Biosciences to license its proprietary CRISPR/Cas9 gene editing platform to develop novel treatments for chronic genetic-based diseases.
Read More
Cell-Free DNA Detection in Histiocytic Disorders May Transform Diagnosis and Treatment
January 8th 2015Langerhans cell histiocytosis (LCH) and Erdheim-Chester disease (ECD) are characterized by a high frequency of BRAFV600E mutations, which are responsive to treatment with BRAF inhibitors such as vemurafenib.
Read More
Gene Test Predicts Risk of Recurrence for DCIS Patients
December 13th 2014A 12-gene test for breast cancer recurrence after ductal carcinoma in situ (DCIS) distinguished high- and intermediate- risk patients from those with a low risk. These results were presented at the 2014 San Antonio Breast Cancer Symposium.
Read More
Next-Generation Sequencing Tests in NSCLC
November 7th 2014A key to improved outcomes for patients with non-small cell lung cancer (NSCLC) is the ability to identify the wide spectrum of genetic changes present in tumors. Doing so will guide treatment decisions and influence the development of much-needed additional targeted therapies.
Read More
Veliparib Demonstrates Clinical Activity in Patients with BRCA-Positive Breast, Ovarian Tumors
September 6th 2014The poly (ADP-ribose) polymerase (PARP) inhibitor veliparib exhibits antitumor activity and is safe and tolerable on a continuous dosing schedule when used for the treatment of patients with BRCA-positive and BRCA-wild type tumors.
Read More
New Insights From ENCODE Datasets, NIH Issues Finalized Genomic Data Sharing Policy
September 2nd 2014A series of papers have been published in the journal Nature in which researchers conducted detailed comparisons of the worm, fly, and human genomes using data from the ENCODE and modENCODE projects.
Read More